Cancer antigen 125 (CA 125) is a 220 000 molecular weight glycoprotein defined by a murine monoclonal antibody OC 125, which was raised against the serous ovarian carcinoma cell line OVCA 433.1 Immunohistochemical studies have shown that CA 125 is expressed by coelomic epithelium during embryonic development and by most ovarian epithelial tumours. CA 125 was detected in the serum samples of about 80% of patients with ovarian cancer.' Subsequently, CA 125 was a clinically useful tumour marker in the follow up of patients treated for ovarian adenocarcinomas.34
However, CA 125 proved not to be a tumour specific antigen, as its presence was shown in the normal epithelium of the female genital tract; in gastric and colonic mucosal cells; and at the luminal surface of mesothelium lining the peritoneum, pleura, and pericardium.5
High concentrations of CA 125 have been found in the sera of patients after abdominal surgery and in patients during episodes of bacterial peritonitis. These chamber inserts (Costar). The filters were precoated with fibronectin before mesothelial cells were added. Mesothelial cell monolayers reached confluence in five days as determined by May-Grunwald-Giemsa staining. Pretreatment of the monolayer with human recombinant interleukin-lfl (rIl-1fl; 25 U/ml; Genzyme Corporation, Boston, Massachusetts, USA) did not influence the microscopic morphology of the confluent monolayer. In all experiments culture medium without antibiotics was used.
Medium was refreshed before adding rIl-1f to either the upper or lower compartment of the Transwell system. At nought and six hours, samples from both compartments were taken and stored at -70°C until tested for CA 125.
To find out whether other stimuli besides rIl-l,B were able to induce the mesothelial cells to secrete CA 125, these were subcultured to confluent monolayers in six well culture dishes (Costar). The wells were incubated with tumour necrosis factor-a (TNF-a; 100 U/ml; Genzyme Corporation), lipopolysaccharide from Escherichia coli (LPS; 1 
